Methodological aspects of cognitive dysfunction diagnosis in patients with systemic lupus erythematosus
Authors:
R. Svobodová 1; M. Pošmurová 1; P. Kozelek 2; M. Olejárová 1
Authors‘ workplace:
Revmatologický ústav Praha, 2Psychiatrická klinika VFN Praha
1
Published in:
Čes. Revmatol., 18, 2010, No. 1, p. 42-47.
Category:
Overview Reports
Overview
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with a broad spectrum of manifestations. Involvement of the nervous system is present in up to 80% of patients with SLE. Diagnosis of neuropsychiatric involvement (NPSLE) is very difficult with regard to a variety of clinical symptoms. Cognitive dysfunction (CD) is one of the most common manifestations of NPSLE. Its cause has not yet been entirely elucidated; a possible role of various autoantibodies, inflammatory mediators, vascular abnormalities, and neuropeptides has been discussed. Diagnosis of cognitive dysfunction is based on the testing of all substantial areas of cognitive functions: perception, attention, memory, motoric and verbal abilities, problem solving, and executive (controlling, also performing) functions (abilities to plan, act effectively, and achieve a goal) are evaluated.
Key words:
systemic lupus erythematosus, neuropsychiatric involvement, cognitive
Sources
1. Briani C, Lucchetta M, Ghirardello A, et al. Neurolupus is associated with anti-ribosomal P protein antibodies: An inception cohort study. Journal of Autoimmunity 2009; 32: 79–84.
2. Denburg SD, Denburg JA, Carbotte RM, et al. Cognitive deficits in systemic lupus erythematosus. Rheum Dis Clin North Am 1993; 19: 815–31.
3. West SG. Lupus and the central nervous system. Curr Opin Rheumatol 1996; 8: 408–14.
4. Hanly JG. Evaluation of patients with CNS involvement in SLE. Clin Rheumatol 1998; 32: 329–332.
5. Khoshbin S, Glanz BI, Schur PH. Neuropsychiatric syndromes in systemic lupus erythematosus: a new look. Clin Exp Rheumatol 1999; 17: 395–8.
6. Bruns A, Meyer O. Neuropsychiatric manifestations of systemic lupus erythematosus. Joint Bone Spine 2006; 73: 639–45.
7. Rood MJ, Breedveld FC, Huizinga TW. The accuracy of diagnosing neuropsychiatric systemic lupus erythematosus in a series of 49 hospitalized patients. Clin exp Rheumatol 1999; 17: 395–8.
8. Gerli R, Caponi L, Tincani A, et al. Clinical and serological associations of ribosomal P protein autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology 2002; 41: 1357–66.
9. ACR ad hoc committee on neuropsychiatric lupus nomenclature „The American College og Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes“. Arhtitis Rheum 1999; 42: 599–608.
10. Magalhaes MG, Silva LM, Voltarelli JC, et al. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations. Scand J Rheumatol 2007; 36: 442–447.
11. Kang EH, Shen GQ, Morris R. Flow cytometric assessment of anti-neuronal antibodies in central nervous system involvement of systemic lupus erythematosus and other autoimmune diseases 2008; 17: 21–25.
12. Johnson RT, Richardson EP: The neurological manifestations of systemic lupus erythematosus. Medicine (baltimore) 1968; 47: 337–369.
13. Hanly JG, Walsh NM, Sangalang V. Brain pathology in systemic lupus erythematosus. J Rheumatol 1992; 19: 732–41.
14. Weiner SM, Klein R, Berg PA. A longitudinal study of autoantibodies against central nervous system tissue and gangliosides in connective tissue diseases. Rheumatol Int 2000; 19: 83–88.
15. Bluestein HG, Williams GW, Steinberg AD. Cerebrospinal fluid antibodies to neuronal cells: association with neuropsyschiatric manifestations of systemic lupus erythematosus. Am J Med 1981; 70: 240–246.
16. Zvaifler NJ, Bleustein HG. The pathogenesis of central nervous system menifestations of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 862–866.
17. Martinez-Cordero E, Garcia BE, Leon DE. Anticardiolipin antibodies in serum and cerebrospinal fluid from patients with systemic lupus erythematosus. J Invest Allergol Clin Immunol 1997; 7: 596–601.
18. Hanly JG, Walsh NM, Fisk J, et al. Cognitive impairment and autoantibodies in systemic lupus erythematosus. Br J Rheumatol 1993; 32: 291–6.
19. Denburg SD, Carbotte RM, Denburg JA. Cognitive impairment in systemic lupus erythematosus: a neuropsychological study of individual and group deficits. J Clin Exp Neuropsychol 1987; 9: 323–39.
20. Omdal R, Brokstad K, Waterloo K, et al. Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptor. Eur J Neurol 2005; 12: 392–8.
21. Lapteva L, Nowak M, Yarboro CH, et al. Anti-N-methyl-D-aspartate receptor antibodies, cognitive dysfunction, and depression in systemic lupus erythematosus. Arthritis Rheum 2006; 54: 2505–14.
22. Hanly JG, Robichaud J, Fisk JD. Anti-NR2 glutamate receptor antibodies and cognitive function in systemic lupus erythematosus. J Rheumatol 2006; 33: 1553–8.
23. Harrison MJ, Ravdin LD, Lockshin MD. Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis rheum 2006; 54: 2515–22.
24. Steup-Beekman G, Steens S van Buchem M, et al. Anti-NMDA receptor autoantibodies in patients with systemic lupus erythematosus and their first-degree relatives. Lupus 2007; 16: 329–34.
25. Arinuma Y, Yanagida T, Hirohata S. Association of cerebrospinal fluid anti-NR2 glutamate receptor antibodies with diffuse neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008; 58: 1130–5.
26. Bonfa E, Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and ant-ribosomal P protein antibodies. N engl J Med 1987; 317: 265–271.
27. Teh LS, Isenberg DA. Antiribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal Arthritis Rheum 1994; 37: 307–315.
28. Isshi K, Hirohata S. Differential roles of the anti-ribosomal P antibody in the pathogenesis of central nervous systém involvement in systemic lupus erythematosus. Arthritis Rheum 1998; 41: 1819–1827.
29. Sato T, Uchiumi T, Ozawa T, et al. Autoantibodies against ribosomal proteins found with high frequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991; 18: 1681–4.
30. Chindalore V, Neas B, Reichlin M. The association between anti-ribosomal P antibodies and active nephritis in systemic lupus erythematosus. Clin Immunol Immunopathol 1998; 87: 292–6.
31. Yoshio T, Hirata D, Onda K, et al. Antiribosomal P protein antibodies in cerebrospinal fluid are associated with neuropsychiatric systemic lupus erythematosus. J Rheumatol 2005; 32: 34–9.
32. Karassa FB, Afeltra A, Ambrozic A, et al. Accuracy of anti-ribosomal P protein antibody testing for the diagnosis os neuropsychiatric systemic lupus erythematosus: an international meta-analysis. Arthritis Rheum 2006; 54: 312–24.
33. Hanly JG, Urowitz MB, Siannis F, et al. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum 2008; 58: 843–53.
34. Toubi E, Shoenfeld Y. Clinical and biological aspects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6: 119–25.
35. Kozora E, Thompson LL, West SG, et al. Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous systém disease. Arthritis Rheum 1996; 39: 2035–45.
36. Love PE, Santoro SA: Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682–98.
37. Petri M. Pathogenesis and treatment of the antiphospholipid antibody syndrome. Med Clin North Am 1997; 81: 151–77.
38. Denburg SD, Carbotte RM, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc 1997; 3: 377–86.
39. Hanly JG, Hong C, Smith S, et al. A prospective analysis of cognitive function and anticardiolipin antibodies in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 728–34.
40. Menon S, Jameson-Shortall E, Newman SP, et al. A longitudinal study of anticardiolipin antibody levels and cognitive funcioning in systemic lupus erythematosus. Arthritis Rheum 1999; 42: 735–41.
41. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990; 33: 644–9.
42. Shiozawa S, Kuroki Y, Kim M, et al. Interferon-alfa in lupus psychosis. Arthritis rheum 1992; 35: 417–22.
43. Trysberg E, Carlsten H, Tarkowski A. Intrathecal cytokines in systemic lupus erythematosus with central nervous system involvement. Lupus 2000; 9: 498–503.
44. Rood MJ, Keijsers V, van der Linden MW, et al. Neuropsychiatric systemic lupus erythematosus is associated with imbalance in interleukin 10 promoter haplotypes. Ann Rheum Dis 1999; 58: 85–9.
45. Gilad R, Lampl Y, Eshel Y, et al. Cerebrospinal fluid soluble interleukine-2 receptor in cerebral lupus. Br J Rheumatol 1997; 36: 190–93.
46. Hirohata S, Hayakawa K. Enhanced interleukin-6 messenger RNA expression by neuronal cells in a patient with neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1999; 42: 2729–30.
47. Ainiala H, Hietaharju A, Dastidar P, et al. Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities. Arthritis Rheum 2004; 50: 858–65.
48. Trysberg E, Blennow K, Zachrisson O. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engangement. Arthritis Res Ther 2004; 6: R551–6.
49. Lapteva L, Yarboro CH. Roebuck-Spencer T, et al. Cognitive dysfunction and serum neuropeptides in systemic lupus erythematosus [abstract]. Arthritis Rheum 2006; 54: Suppl 9: S293.
50. Ainiala H, Hietaharju A, Loukkola J, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthirits Rheum 2001; 45: 419–23.
51. Brey RL,Holliday SL, Saklad AR, et al. Neuropsychiatric syndromes in lupus. Prevalence using standardized definitions. Neurology 2002; 58(8): 1214–20.
52. Glanz BI, Schur PH, Lew RA, Khoshbin S. Lateralized cognitive dysfunction in patients with systemic lupus erythematosus. Lupus 2005; 14(11): 896–902.
53. Hanly JG, Liang MH. Cognitive disorders in systemic lupus erythematosus. Epidemiologic and clinical issues. Ann N Y Acad Sci 1997; 823: 60–8.
54. Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus 2003; 12: 883–90.
55. Denburg SD, Carbotte RM, Denburg JA. Psychological aspects of systemic lupus erythematosus: cognitive function, mood, and self-report. J Rheumatol 1997; 24: 998–1003.
56. Tůma I. Schizofrenie a kognitivní funkce. Psychiatrické centrum Praha, 1999.
57. Kozora E, Laudenslager M, Lemieux A, et al. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. J Int Neuropsychol soc 2001; 7: 745–54.
58. Fisk J, eastwood B, Sherwood G, et al. Patterns of cognitive impairment in patients with systemic lupus erythematosus. Br J Rheumatol 1993; 33(Suppl): S103.
59. Miguel EC, Pereira RM, Pereira CA, et al. Psychiatric manifestations of systemic lupus erythematosus: clinical features, symptoms, and signs of central nervous system activity in 43 patients. Medicine 1994; 73: 224–32.
60. Kozora E, Ellison MC, West S. Depression, fatigue, and pain in systemic lupus erythematosus (SLE): relationship to the American College of Rheumatology SLE neuropsychological battery. Arthritis Rheum 2006; 55: 628–35.
61. Harrison MJ, Morris KA, Horton R, et al. Results of intrevention for lupus patients with self-perceived cognitive difficulties. Neurology 2005; 65: 1325–7.
62. WAIS-R. Wechslerův inteligenční test pro dospělé. Příručka. Autoři českého manuálu Říčan P, Šebek M, Vágnerová M. Psychodiagnostické a didaktické testy, Bratislava, 1983.
63. WMS-III. Wechslerova paměťová škála – třetí vydání. Technická příručka pro WAIS-III a WMS-III. Příručka pro administrování a skórování WMS-III. Experimentální verze. Překlad z angličtiny. Psychodiagnostika, Brno, 1999.
64. Reyova-Oesterriethova komplexní figura – TKF. Příručka k testu. Autoři českého manuálu Košč M, Novák J. Psychodiagnostika, Brno, 1997.
65. Test cesty. Trail Making Test. Příručka pro děti i dospělé. Autoři českého manuálu Preiss M, Preiss J, Panamá J. Psychodiagnostika, Brno, 1997. (Autoři testu Reitan R, Volfsonová D).
66. Mitrushina M, Boone KB, Razani J, DęElia LF. Handbook of Normative Data for Neuropsychological Assessment. Second Edition. Oxford University Press, 2005.
67. Preiss M, Rodriguez M, Kawaciuková R, Laing H. Neuropsychologická baterie Psychiatrického centra Praha. Klinické vyšetření základních kognitivních funkcí. 2., přepracované vydání. Psychiatrické centrum Praha, 2007.
68. Fastenau PS, Denburg NL, Hufford BJ. Adult norms for the Rey-Oesterrieth Complex Figure Test and for supplemental recognition and matching trials from the extended Complex Figure Test. The Clinical Neuropsychologist 1999; 13(1): 30–47.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2010 Issue 1
Most read in this issue
- Can the determination of serum procalcitonin be helpful in the differential diagnosis of an infection and an acute exacerbation in patients with a systemic autoimmune disease?
- Prediction of radiographic progression of rheumatoid arthritis
- Significance of vitamin D for human health
- Methodological aspects of cognitive dysfunction diagnosis in patients with systemic lupus erythematosus